İlknur Deliktaş Onur, Pınar Özdemir Akdur, Elif Sertesen Çamöz, Nazan Çiledağ, Fatih Yıldız
{"title":"Evaluation of the prognostic effectiveness of liver metastasis volume by volumetric measurement in colorectal cancer.","authors":"İlknur Deliktaş Onur, Pınar Özdemir Akdur, Elif Sertesen Çamöz, Nazan Çiledağ, Fatih Yıldız","doi":"10.1080/14796694.2024.2406221","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> To evaluate the relationship between liver metastasis volume and survival in colorectal cancer patients using the volumetric measurement method.<b>Methods:</b> 114 colorectal cancer patients with isolated liver metastases were included in the study. Liver tumor volume, total liver volume were calculated from the patients images at the time of diagnosis. Vitrea 7.14 imaging software was used for liver volume analysis and volume analysis of each metastasis.<b>Results:</b> Median overall survival(OS) in the group with tumor volume <42 ml<sup>3</sup> was 30.98 months In the group with tumor volume ≥42 ml<sup>3</sup>, median OS was 16.36 months (<i>p</i>: 0.001). In patients who underwent metastasectomy, the median OS in the group with a tumor volume <42 ml<sup>3</sup> was 52.3 months, the median OS in the group with a tumor volume ≥42 ml<sup>3</sup> was 22.2 months. In patients who did not undergo metastasectomy, the median OS in the <42 ml<sup>3</sup> group was 20.23 months, the median OS in the ≥42 ml<sup>3</sup> group was 15.63 months.<b>Conclusion:</b> In our study, we found that liver metastasis volume was prognostic for OS. It is argued that tumor volume measurement by volumetric measurement is a widely used method in the decision for metastasectomy in liver metastatic colorectal cancer patients.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-8"},"PeriodicalIF":3.0000,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2406221","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: To evaluate the relationship between liver metastasis volume and survival in colorectal cancer patients using the volumetric measurement method.Methods: 114 colorectal cancer patients with isolated liver metastases were included in the study. Liver tumor volume, total liver volume were calculated from the patients images at the time of diagnosis. Vitrea 7.14 imaging software was used for liver volume analysis and volume analysis of each metastasis.Results: Median overall survival(OS) in the group with tumor volume <42 ml3 was 30.98 months In the group with tumor volume ≥42 ml3, median OS was 16.36 months (p: 0.001). In patients who underwent metastasectomy, the median OS in the group with a tumor volume <42 ml3 was 52.3 months, the median OS in the group with a tumor volume ≥42 ml3 was 22.2 months. In patients who did not undergo metastasectomy, the median OS in the <42 ml3 group was 20.23 months, the median OS in the ≥42 ml3 group was 15.63 months.Conclusion: In our study, we found that liver metastasis volume was prognostic for OS. It is argued that tumor volume measurement by volumetric measurement is a widely used method in the decision for metastasectomy in liver metastatic colorectal cancer patients.
期刊介绍:
Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.
The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.